BC Extra | Oct 18, 2008
Clinical News

Boehringer unveils diabetes pipeline

Boehringer Ingelheim (Ingelheim, Germany) announced its entrance into the Type II diabetes drug development space as it unveiled three products in late-stage testing. The compounds include: Ondero ( BI 1356 ), a dipeptidyl peptidase-4 (DPP-4) inhibitor...
Items per page:
1 - 1 of 1